DIPEPTIDYL DIPEPTIDASE-4: VIEW OF THE CLINICAL PHARMACOLOGIST
نویسندگان
چکیده
منابع مشابه
The clinical pharmacologist.
THE controversy over prescribing drugs by their trade or approved names is a source of embarrassment to teachers of therapeutics like myselfwho have, for many years, taught medical students and young doctors to prescribe by approved names, leaving the choice of preparation to the pharmacist, on the assumption that 'the drug is the same'. Today we have to eat our words and recognize, in Sir Phil...
متن کاملDipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1–based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are orally active and increase levels of active GLP-1, which in turn increases insulin secretion and r...
متن کاملDipeptidyl Peptidase-4 Inhibitor
In the United States, nearly 13% of adults aged 20 years and older have type 2 diabetes mellitus (T2DM), and its prevalence is still increasing (1,2). Microvascular and macrovascular abnormalities are common in patients with T2DM and are related to the severity and duration of hyperglycemia (3–5). Thus, treatment of hyperglycemia is an important way to prevent or delay diabetic vascular complic...
متن کاملPharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Saxagliptin is a potent, selective, reversible dipeptidyl peptidase 4 (DPP4) inhibitor specifically designed for extended inhibition of the DPP4 enzyme and is currently under development for the treatment of type-2 diabetes. The pharmacokinetics of saxagliptin were evaluated in rats, dogs, and monkeys and used to predict its human pharmacokinetics. Saxagliptin was rapidly absorbed and had good ...
متن کاملInhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
DPP-4 (dipeptidyl peptidase-4) degrades the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide), decreasing their stimulatory effects on beta-cell insulin secretion. In patients with Type 2 diabetes, meal-related GLP-1 secretion is reduced. DPP-4 inhibitors (alogliptin, saxagliptin, sitagliptin and vildagliptin) correct the GLP-1 deficiency by blocking thi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Council
سال: 2016
ISSN: 2079-701X
DOI: 10.21518/2079-701x-2016-19-114-121